NCT00138203View on ClinicalTrials.gov

Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Recurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
DRUG

vorinostat

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (5)

53715

UW Health Oncology - 1 South Park, Madison

53792

University of Wisconsin Hospital and Clinics, Madison

54221

Holy Family Memorial Hospital, Manitowoc

54601

Gundersen Lutheran, La Crosse

54307-3508

St. Vincent Regional Cancer Center CCOP, Green Bay

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00138203 - Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter